← Human Trials & Peer-Reviewed Studies
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial
Plain-language guide to PMID 18263663 (2008): open-label randomized controlled trial study of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 18263663
- Journal
- Thorax
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Aubin HJ et al. (8 authors)
- DOI
- 10.1136/thx.2007.090647
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
A study was undertaken to compare a 12-week standard regimen of varenicline with a 10-week standard regimen of transdermal nicotine replacement therapy (NRT) for smoking cessation.
Who Took Part
By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.
Non-treatment follow-up continued to week 52.
Secondary outcomes included CAR from the last 4 weeks of treatment through weeks 24 and 52, and measures of craving, withdrawal and smoking satisfaction.
How the Study Was Run
The researchers set it up as a randomized, open-label, placebo-controlled and multicenter study.
Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.
Everyone knew when Therapeutic nicotine (patch, non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.
More than one site took part, so the participants came from several places.
What Was Measured
The subject headings attached to it are Administration, Cutaneous, Benzazepines, Nicotine, Nicotinic Agonists, Patient Compliance, Quinoxalines and Reinforcement, Psychology.
What This Means in Plain Language
The paper is a randomized, open-label and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2008 (Thorax), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.